Skip to main content
Premium Trial:

Request an Annual Quote

CDC Will Develop Bacterial Assays With Nanogen System

NEW YORK, June 6-Nanogen said today that it will work with the U.S. Centers for Disease Control to adapt its chip-based system to detection of diarrheal Escherichia coli and other pathogens.

 

Nanogen will install one of its NanoChip workstations at the CDC's Foodborne and Diarrheal Diseases Branch in Atlanta, Ga. Under a "Development Site Agreement," CDC researchers will have preferential access to Nanogen technology as they develop assays for particular strains of pathogenic bacteria.

 

Nanogen receives licensing and commercialization rights to these assays, and may use this research to develop other diagnostic tests.

 

At the end of the program, the CDC will have an option to purchase the Nanogen system.

 

For more details, see the press release.

 

 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.